Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoxanthopterin SCHEMBL4389432 | 0.68 | PIK3CG (0.46) | PIK3CGKDM4E | |
| SCHEMBL12292807 | 0.68 | KDM4E (0.31) | KDM4E | |
| SCHEMBL5257430 | 0.67 | GUSB (0.33) | KDM4E | |
| SCHEMBL20746698 | 0.64 | MMP2 (0.33) | — | |
| SCHEMBL25306400 | 0.63 | DYRK1B (0.41) | — | |
| SCHEMBL12847495 | 0.63 | CCR1 (0.38) | KDM4EL3MBTL1 | |
| SCHEMBL17326037 | 0.63 | KDM4E (0.34) | KDM4EL3MBTL1 | |
| SCHEMBL16548015 | 0.62 | — | — | |
| SCHEMBL9196608 | 0.61 | AKR1B1 (0.40) | KDM4E | |
| SCHEMBL5257685 | 0.60 | KDM4E (0.50) | KDM4ENPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188877-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188877-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | F2RL3, PARP14, F2R | PIK3CG 1029/4885KDM4E 1720/4885NPC1 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.